# Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment

> **NCT02471222** · PHASE2 · COMPLETED · sponsor: **Adamas Pharmaceuticals, Inc.** · enrollment: 60 (actual)

## Conditions studied

- Walking Impairment
- Multiple Sclerosis

## Interventions

- **DRUG:** ADS-5102
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02471222
- **Lead sponsor:** Adamas Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2017-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02471222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02471222, "Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02471222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*